RGENIX Shows Clinical Activity of Novel Agent RGX-202 in Patients with KRAS Mutant Colorectal Cancer in Phase 1 Trial
NEW YORK , May 29 /Businesswire/ - Today @RGENIX, a clinical stage biopharma developing first-in-class small molecule and antibody cancer therapeutics, presented data at #ASCO20 showing clinical activity in patients with advanced KRAS mutant colorectal cancer with novel RGX-202 compound.